Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Investing Activities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Cash from Investing Activities for 7 consecutive years, with -$14.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 343.44% to -$14.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.5 million through Dec 2025, down 140.29% year-over-year, with the annual reading at -$24.5 million for FY2025, 140.29% down from the prior year.
  • Cash from Investing Activities hit -$14.4 million in Q4 2025 for BridgeBio Pharma, down from $4.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $149.7 million in Q2 2022 to a low of -$282.1 million in Q1 2021.
  • Historically, Cash from Investing Activities has averaged $17.1 million across 5 years, with a median of $8.4 million in 2023.
  • Biggest five-year swings in Cash from Investing Activities: surged 32586.03% in 2022 and later tumbled 4804.55% in 2024.
  • Year by year, Cash from Investing Activities stood at $21.8 million in 2021, then fell by 17.59% to $18.0 million in 2022, then tumbled by 100.37% to -$66000.0 in 2023, then crashed by 4804.55% to -$3.2 million in 2024, then tumbled by 343.44% to -$14.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for BBIO at -$14.4 million in Q4 2025, $4.5 million in Q3 2025, and -$13.0 million in Q2 2025.